SEC Form 4 · accession 0001415889-18-001039
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kurt A Gustafson
Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 8:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $3.83 | Jun 22, 2018 | A | 20,000 | A | Jun 22, 2019 | Jun 22, 2028 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Options vest 100% on June 22, 2019.